secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivani Medical, Inc. (VANI)
CIK:        0001266806
Form:       8-K
Filed at:   2026-07-07T11:46:22+00:00
Accession:  0001753926-26-001144
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivani subsidiary Cortigent to merge into ClearOne in stock deal; Novo Nordisk to evaluate semaglutide implant
--------------------------------------------------------------------------------

- Cortigent (Vivani subsidiary) to merge into ClearOne (Nasdaq: CLRO) for 12.5M ClearOne shares; Vivani will control combined board.
- ClearOne to raise $10M-$15M via unit offering as condition to close; closing expected by Dec 28, 2026.
- Vivani enters non-exclusive agreement with Novo Nordisk to evaluate NPM-139 semaglutide implant for chronic weight management.
- Phase 1 first-in-human study of NPM-139 expected mid-2026 with Wegovy as active comparator.
- Lock-up: 50% of Vivani's ClearOne shares locked 1 year, 50% locked 2 years.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1266806/000175392626001144/0001753926-26-001144-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1266806/000175392626001144/vani-20260701.htm
  HTML page:      https://secwatch.observer/filing/0001753926-26-001144

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer